Exchange: OTC·Updated 08:05 AM EDT

NWPHF Newron Pharmaceuticals Spa.

$20.00
$0.8874
(4.44%)
Pre-Market
Prev Close $20.00
EarningsMar 22
Mkt Cap$424.78M
Vol50.00

About NWPHF

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.
55

Bullish Sentiment

How do you feel about NWPHF?

flybyme
$NWPHF Now the waiting game, Beginning of Jan. 2027 end of tests phase 3 first one. Fda should lift ban soon. Price seems to have found its range.
1
flybyme
$NWPHF Its Friday the last bad news about the Fda hold was on a friday.Theres chat they were expecting an answer today.I hope it will be positive, make up for the last screw up.

Advertisement|Remove ads.